Antisense technology changed one devastating disease. Why hasn’t it transformed others?

The 2016 meeting of the Oligonucleotide Therapeutics Society in Montreal began with a rare mix of promise and elation.

That year, the 27-year-old biotech Ionis showed that a drug, later branded Spinraza, could dramatically alter the course of spinal muscular atrophy, a genetic condition that killed most diagnosed children before...

Click to view original post